Cutting-Edge Therapies Context Therapeutics is at the forefront of developing innovative T cell engaging antibodies for solid tumors, such as CTIM-76 and BA3362, presenting a prime opportunity for collaboration and partnerships.
Expert Leadership Team With key appointments like Dr. Karen Smith, Dr. Luke Walker, and Claudio Dansky Ullmann, Context Therapeutics boasts a seasoned leadership team that can facilitate strategic discussions and drive business growth.
Strategic Funding Recent $100 million private placement led by Nextech underscores investor confidence in Context Therapeutics' potential, opening avenues for strategic alliances or investment opportunities.
Expansion Plans The addition of new talent like Karen Andreas as VP of Clinical Operations signifies Context Therapeutics' growth trajectory, signaling a need for services that support expanding clinical operations and research efforts.
Competitive Advantage With a focus on developing targeted therapies for solid tumors and positioning themselves alongside similar successful companies like GW Pharmaceuticals plc, Context Therapeutics presents a competitive edge in a niche market segment.
Context Therapeutics uses 8 technology products and services including Google Analytics, Squarespace, Typekit, and more. Explore Context Therapeutics's tech stack below.
| Context Therapeutics Email Formats | Percentage |
| FLast@contexttherapeutics.com | 50% |
| FLast@contexttherapeutics.com | 50% |
Biotechnology ResearchPennsylvania, United States11-50 Employees
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing medicines for solid tumors. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, currently in preclinical development. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.
Company Overview
Media & News
Funding & FinancialsContext Therapeutics has raised a total of $100M of funding over 3 rounds. Their latest funding round was raised on May 02, 2024 in the amount of $100M.
Funding & FinancialsContext Therapeutics has raised a total of $100M of funding over 3 rounds. Their latest funding round was raised on May 02, 2024 in the amount of $100M.
1-888-653-2347 
support@leadiq.com